Calhoun Vision, Inc., is the world leader in adjustable intraocular lens technology. Calhoun's proprietary technology utilizes light to enable surgeons to change the power of a lens after it has been implanted. This offers the potential to provide unparalleled visual outcomes and customization to the specific visual needs of each patient.
This month, the Company raised $69 million in financing to continue supporting the FDA pre-market process and for executing on the Company's strategy to transform the landscape of cataract surgery. Also, Chief Executive Officer, Rick A. Heinick, recently named Ron Kurtz, M.D. and Eric Weinberg to the positions of Chief Operations Officer and Chief Commercial Officer.
In the United States, the Food and Drug Administration (FDA) must first approve the lens before it can be marketed commercially. Calhoun Vision has completed Phases I and II of the required clinical investigation; the third and final phase of study has commenced, and all subjects have been fully enrolled in the study.